Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.46 |
| ▸ | ESRRG | P62508 | 2/20 | 0.39 |
| ▸ | ESRRB | O95718 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20842182 | 0.73 | SLC18A3 (0.47) | ALKSLC18A3ESRRGESRRBESR1 | |
| SCHEMBL5453321 | 0.70 | HRH3 (0.48) | HRH3KDM2BKCNH2 | |
| SCHEMBL20156527 | 0.70 | QDPR (0.50) | HRH3KCNH2 | |
| SCHEMBL13470480 | 0.70 | CYP11B2 (0.42) | HRH3KCNH2 | |
| SCHEMBL6132351 | 0.70 | SLC18A3 (0.63) | HRH3SLC18A3ESRRGESRRBESR1 | |
| SCHEMBL19374270 | 0.70 | TGFBR1 (0.40) | SLC18A3 | |
| SCHEMBL20131029 | 0.69 | PIK3CD (0.42) | SLC18A3HSD11B1KDM2B | |
| SCHEMBL21026812 | 0.69 | SLC18A3 (0.46) | ALKSLC18A3ESRRGESRRBESR1 | |
| SCHEMBL5805903 | 0.68 | NAMPT (0.47) | HRH3KCNH2 | |
| SCHEMBL17670005 | 0.67 | KIF11 (0.40) | HRH3HSD11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | HRH3 1440/4885ALK 4339/4885SLC18A3 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.